The specter of generic competition has consistently loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the future of connected pharmaceutical portfolios. While early times saw substantial returns, the intellectual property get more info end has opened the door for less expensive copies, possibly diminishing earnin